secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K/A
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001437749-25-035597
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.01, 9.01, 8.01, 9.0
LLM model:  deepseek-v4-flash:cloud@v2

Eton files historical financials for Increlex acquisition; product net sales $18.7M in 2023
--------------------------------------------------------------------------------

- Acquired Increlex for $22.5M upfront plus $7.5M inventory; $2.5M payments on 1st & 2nd anniversaries.
- Expanded credit facility to $30M, maturity 3 years, SOFR+6.75%; issued warrant for 289,736 shares at $5.32.
- Increlex net sales: $18.7M (2023), $15.1M (2022); nine months Sep 2024 $13.0M vs $13.9M prior.
- Pro forma combined net loss for nine months Sep 2024: $5.5M vs Eton historical $3.2M.
- Increlex net sales exceeded direct expenses: $3.9M in 2023, $4.1M in nine months Sep 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925035597/0001437749-25-035597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925035597/eton20250314_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-035597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer